Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.
ClinicalTrials.gov ID: NCT00312104
Organization: Novo Nordisk A/S
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Diabetes
Diabetes Mellitus, Type 1
Interventions: DRUG: insulin detemir
DRUG: insulin glargine
DRUG: insulin aspart
Lead sponsor: Novo Nordisk A/S (INDUSTRY)
Enrollment: 325 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2002-04
Completion date: 2003-03
Locations:
facility: Novo Nordisk Investigational Site
city: Graz
country: Austria
facility: Novo Nordisk Investigational Site
city: Vienna
country: Austria
facility: Novo Nordisk Investigational Site
city: Vienna
country: Austria
facility: Novo Nordisk Investigational Site
city: Vienna
country: Austria
facility: Novo Nordisk Investigational Site
city: Vienna
country: Austria
facility: Novo Nordisk Investigational Site
city: Bad Kreuznach
country: Germany
facility: Novo Nordisk Investigational Site
city: Bad Mergentheim
country: Germany
facility: Novo Nordisk Investigational Site
city: Bad Neuenahr-Ahrweiler
country: Germany
facility: Novo Nordisk Investigational Site
city: Berlin
country: Germany
facility: Novo Nordisk Investigational Site
city: Diez
country: Germany
facility: Novo Nordisk Investigational Site
city: Erlangen
country: Germany
facility: Novo Nordisk Investigational Site
city: Essen
country: Germany
facility: Novo Nordisk Investigational Site
city: Flensburg
country: Germany
facility: Novo Nordisk Investigational Site
city: Frankfurt
country: Germany
facility: Novo Nordisk Investigational Site
city: Friedrichsthal
country: Germany
facility: Novo Nordisk Investigational Site
city: Genthin
country: Germany
facility: Novo Nordisk Investigational Site
city: Halle
country: Germany
facility: Novo Nordisk Investigational Site
city: Hamburg
country: Germany
facility: Novo Nordisk Investigational Site
city: Hanover
country: Germany
facility: Novo Nordisk Investigational Site
city: Heidelberg
country: Germany
facility: Novo Nordisk Investigational Site
city: Hennigsdorf
country: Germany
facility: Novo Nordisk Investigational Site
city: Hünxe
country: Germany
facility: Novo Nordisk Investigational Site
city: Jena
country: Germany
facility: Novo Nordisk Investigational Site
city: Kiel
country: Germany
facility: Novo Nordisk Investigational Site
city: Landau
country: Germany
facility: Novo Nordisk Investigational Site
city: Ludwigshafen
country: Germany
facility: Novo Nordisk Investigational Site
city: Marl
country: Germany
facility: Novo Nordisk Investigational Site
city: Mönchengladbach
country: Germany
facility: Novo Nordisk Investigational Site
city: Neunkirchen
country: Germany
facility: Novo Nordisk Investigational Site
city: Neuss
country: Germany
facility: Novo Nordisk Investigational Site
city: Northeim
country: Germany
facility: Novo Nordisk Investigational Site
city: Nuremberg
country: Germany
facility: Novo Nordisk Investigational Site
city: Rehlingen-Siersburg
country: Germany
facility: Novo Nordisk Investigational Site
city: Rheda-Wiedenbrück
country: Germany
facility: Novo Nordisk Investigational Site
city: Saarbrücken
country: Germany
facility: Novo Nordisk Investigational Site
city: Saarlouis
country: Germany
facility: Novo Nordisk Investigational Site
city: Schönebeck
country: Germany
facility: Novo Nordisk Investigational Site
city: Schwabenheim
country: Germany
facility: Novo Nordisk Investigational Site
city: Schwerin
country: Germany
facility: Novo Nordisk Investigational Site
city: Völklingen
country: Germany
facility: Novo Nordisk Investigational Site
city: Wiesbaden
country: Germany
facility: Novo Nordisk Investigational Site
city: Würzburg
country: Germany
facility: Novo Nordisk Investigational Site
city: Johannesburg
state: Gauteng
country: South Africa
facility: Novo Nordisk Investigational Site
city: Durban
state: KwaZulu-Natal
country: South Africa
facility: Novo Nordisk Investigational Site
city: Cape Town
state: Western Cape
country: South Africa
facility: Novo Nordisk Investigational Site
city: Cape Town
state: Western Cape
country: South Africa

Summary:
The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes.